Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley E Shackney

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Intracellular patterns of Her-2/neu, ras, and ploidy abnormalities in primary human breast cancers predict postoperative clinical disease-free survivalStanley E Shackney, Charles A Smith, Agnese Pollice, et al.
Molecular Cancer Therapeutics|October 17, 2007
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell linesDavid R Emlet, Kathryn A Brown, Deborah L Kociban, et al.
Human Pathology|February 2, 2002
Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancerHelen Han, Rodney J Landreneau, Tibetha S Santucci, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Intracellular patterns of Her-2/neu, ras, and ploidy abnormalities in primary human breast cancers predict postoperative clinical disease-free survivalStanley E Shackney, Charles A Smith, Agnese Pollice, et al.
Molecular Cancer Therapeutics|October 17, 2007
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell linesDavid R Emlet, Kathryn A Brown, Deborah L Kociban, et al.
Human Pathology|February 2, 2002
Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancerHelen Han, Rodney J Landreneau, Tibetha S Santucci, et al.
Pageof 2